Adaptive Biotechnologies Corporation (ADPT) FinancialsADPTAdaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MRD revenue, accounting for 94.7% of total sales, equivalent to $67.09M. Another important revenue stream is Immune meidicine revenue. Understanding this composition is critical for investors evaluating how ADPT navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Adaptive Biotechnologies Corporation maintains a gross margin of 71.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -21.93%, while the net margin is -55.82%. These profitability ratios, combined with a Return on Equity (ROE) of -39.58%, provide a clear picture of how effectively ADPT converts its operational activities into shareholder value.

In the context of the broader market, ADPT competes directly with industry leaders such as EWTX and ABCL. With a market capitalization of $4.29B, it holds a leading position in the sector. When comparing efficiency, ADPT's gross margin of 71.23% stands against EWTX's N/A and ABCL's 100.00%. Such benchmarking helps identify whether Adaptive Biotechnologies Corporation is trading at a premium or discount relative to its financial performance.

The company has demonstrated significant revenue growth, with Q2 2026 revenue at $71.55 million, contributing to a year-to-date change of +66.50%. The gross margin is also strong at 71.23%, indicating efficient cost management.